. . . . . . . . . "Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug." . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "On7YSpaFsTsY4i1/nawDQAYXt/oiwbNk0NI24hf1uQcWE2ATujgLg+EuS3EeNxSgIBBR5xyJTAAOCX5rie1P1sh5BE/h1PmIc/jhtNNB99vSzDY9ZcVFo9cHKm/TTuhI5vZH79/DDLs3nk6opW6OFs2liYiu4yfMNbSzXyZP2Js=" . . "2021-08-25T14:33:31.025+02:00"^^ . . . . .